Avedro has completed a $43 million Series D financing led by Abingworth along with a significant investment by Third Point. Avedro’s other investors include Prism Venture Works, De Novo Ventures, Flagship Ventures, Aperture Ventures, SCP Vitalife Partners, Borealis Ventures and Echelon Ventures. As part of the transaction, David Mayer from Abingworth and Jason Hong, PhD from Third Point will be joining the board of directors.

Labcyte, a privately-held company advancing acoustic liquid handling, has closed a Series D financing led by the healthymagination fund, a part of GE Ventures. The $5.3 million round also included current Labcyte investors – Abingworth, Alloy Ventures, Cross Atlantic Partners, Delphi Ventures, H&Q Healthcare Investors and H&Q Life Sciences Investors.

Summit, New Jersey-headquartered Celgene Corporation is to acquire Avila Therapeutics, a privately held biotechnology company. Avila is backed by Abingworth, Advent Venture Partners, Atlas Venture, Novartis Option Fund, and Polaris Venture Partners. PRESS RELEASE Celgene Corporation (NASDAQ: CELG) and Avila Therapeutics, Inc., a privately held biotechnology company developing targeted covalent drugs that treat diseases through [...]

Prosensa, a Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases, has raised €23 million (US$29.8 million) in new equity financing. The financing was led by new investor New Enterprise Associates (NEA) and was supported by existing investors, Abingworth, Life Sciences Partners, Gimv, Idinvest Partners and MedSciences Capital. PRESS RELEASE Prosensa, the Dutch biopharmaceutical [...]

Takeda Pharmaceutical Company, a listed, Japanese pharmaceutical research company, is buying venture-backed Intellikine Inc. Takeda will pay $190 million in cash, and up to $120 million in additional milestone payments. Intellikine was backed by at least $41 million from venture investors including Abingworth, BiogenIdec, CMEA Capital, Fintech Global Capital, Novartis Venture Funds, Sofinnova Ventures and U.S. Venture Partners.

Biopharma company Intellikine Inc. has sealed $4 million in new milestone payments as it begins two Phase 1 clinical trials of its drugs. The company, based in La Jolla, Calif., is backed by $41 million from venture investors including Abingworth, BiogenIdec, CMEA Capital, Fintech Global Capital, Novartis Venture Funds, Sofinnova Ventures and U.S. Venture Partners.

Healthcare Brands International has sold its Antula Healthcare to specialty pharma company Meda AB for about $288 million. Healthcare Brands International was formed in 2006, and has raised capital from investors including Essex Woodlands, MVM Life Science Partners, Sofinnova Partners and Abingworth. The company bought Antual Healthcare in late 2007.

Secure EDI, a Charlotte, N.C.-based healthcare IT company, has raised $40 million in growth equity funding from Abingworth.

Clovis Oncology, a developer of anti-cancer agents based in Boulder, Colo., secured $145 million in financing from Domain Associates, New Enterprise Associates (NEA), Versant Ventures, Aberdare Ventures, Abingworth, Frazier Healthcare Ventures, ProQuest Investments and the Company’s management team. Press release: Clovis Oncology, Inc., a company focused on acquiring, developing and commercializing innovative anti-cancer agents in [...]

Algeta ASA (OSE: ALGETA), a Norway-based cancer therapeutics company, has raised $35 million via a private placement of 22.3 million new shares. Venture capital firm Abingworth led the round. PRESS RELEASE Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that it has raised USD 35 million (NOK 245 million) through the Private Placement of [...]